Brief: Kymera Therapeutics Announces First Patient Dosed In Breadth Phase 2B Asthma Clinical Trial Of KT-621, A First-In-Class, Oral Stat6 Degrader
29/01/2026 12:23
Jan 29 (Reuters) - Kymera Therapeutics Inc KYMR.O: KYMERA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN BREADTH PHASE 2B ASTHMA CLINICAL TRIAL OF KT-621, A FIRST-IN-CLASS, ORAL STAT6 DEGRADER KYMERA THERAPEUTICS INC - EXPECTS BROADEN2 TRIAL DATA BY MID-2027 KYMERA THERAPEUTICS INC - EXPECTS BREADTH TRIAL DATA IN LATE-2027 Source text: ID:nGNX5xsHB3 Further company coverage: KYMR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kymera Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Kymera Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates
Brief: Kymera Therapeutics Q2 EPS USD -0.62
Brief: Kymera Therapeutics Appoints Terence Rooney, MD, As Chief Medical Officer